Multiple sclerosis care units in Latin America: Consensus recommendations about its objectives and functioning implementation.

OBJECTIVE: Currently, there are several reasons to promote worldwide the concept of multiple sclerosis care units (MSCU) for a better management of affected patients. Ideally, the MSCU should have some human and technical resources that distinguish and improve the care of affected patients; however, local, and regional aspects should be considered when recommending how these units should operate. The objective of these consensus recommendations was to review how MSCU should work in Latin America to improve long-term outcomes in MS patients. METHODS: A panel of neurology experts from Latin America dedicated to the diagnosis and care of MS patients gathered virtually during 2019 and 2020 to carry out a consensus recommendation about objectives and functioning implementation of MSCU in Latin America. To achieve consensus, the methodology of "formal consensus-RAND/UCLA method" was used. RESULTS: Recommendations focused on the objectives, human and technical resources, and the general functioning that MSCU should have in Latin America. CONCLUSIONS: The recommendations of these consensus guidelines attempt to optimize the health care and management of MS patients by setting how MSCU should work in our region.

Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America.

BACKGROUND: Despite the abundance of information concerning ocrelizumab in phase III clinical trials, there is scarce evidence regarding real-world patient profiles. OBJECTIVE: The aim of this study was to investigate patient profiles, effectiveness and persistence with treatment among patients who used ocrelizumab for treatment of multiple sclerosis in Latin America. METHODS: This was a retrospective multicenter study in Argentina, Chile and Mexico. Medical record databases on patients who received ocrelizumab were analyzed. Demographic and clinical variables were described, along with effectiveness outcomes, which included the proportions of patients free from clinical relapses, from disability progression and from new or enlarging T2 or T1 gadolinium-enhancing lesions, on annual magnetic resonance imaging. RESULTS: A total of 81 patients were included. The most frequent phenotype was relapsing-remitting MS, in 64.2% of the patients. The mean age at study entry was 41.3 ± 12.0 years and 51.8% were women. A total of 38% had had relapse activity during the 12 months before starting on ocrelizumab, with a mean relapse rate of 1.3 ± 0.6 during that period. 75% were free from clinical relapses and 91% were free from gadolinium-enhancing lesions in the relapsing-remitting course. Ocrelizumab discontinuation during the first 12 months was observed in three patients (3.7%). The mean persistence observed during the first-year follow-up was 338 ± 24 days. CONCLUSIONS: Our study is in line with previous randomized clinical trials and recent real-world studies describing patient profiles, effectiveness and persistence regarding ocrelizumab treatment in multiple sclerosis patients in Latin America.

Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care: Research priorities in MS in LATAM.

As human and economic resources are limited, especially in Latin America (LATAM), it is important to identify research priorities to improve multiple sclerosis (MS) patients care in the region. The objective was to generate a multidisciplinary consensus on research priorities in MS for patients care in LATAM by involving healthcare professionals and MS patient associations. METHODS: consensus was reached through a four-step modified Delphi method designed to identify and rate research priorities in MS in LATAM. The process consisted of two qualitative assessments, a general ranking phase and a consensus meeting followed by a more detailed ranking phase RESULTS: a total of 62 participants (35 neurologists, 4 nurses, 12 kinesiologists, 7 neuropsychologists and 4 patient association members) developed the process. At the final ranking stage following the consensus meeting, each participant provided their final rankings, and the top priority research questions were outlined. 11 research priorities were identified focusing on healthcare access, costs of the disease, physical and cognitive evaluation and rehabilitation, quality of life, symptoms management, prognostic factors, the need of MS care units and patient's management in emergencies like COVID-19. CONCLUSION: this work establishes MS research priorities in LATAM from multiple perspectives. To pursue the actions suggested could launch the drive to obtain information that will help us to better understand the disease in our region and, especially, to better care for affected patients.

Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America / Experiencia en la vida real con el uso de ocrelizumab en pacientes con esclerosis múltiple en Latinoamérica

ABSTRACT Background: Despite the abundance of information concerning ocrelizumab in phase III clinical trials, there is scarce evidence regarding real-world patient profiles. Objective: The aim of this study was to investigate patient profiles, effectiveness and persistence with treatment among patients who used ocrelizumab for treatment of multiple sclerosis in Latin America. Methods: This was a retrospective multicenter study in Argentina, Chile and Mexico. Medical record databases on patients who received ocrelizumab were analyzed. Demographic and clinical variables were described, along with effectiveness outcomes, which included the proportions of patients free from clinical relapses, from disability progression and from new or enlarging T2 or T1 gadolinium-enhancing lesions, on annual magnetic resonance imaging. Results: A total of 81 patients were included. The most frequent phenotype was relapsing-remitting MS, in 64.2% of the patients. The mean age at study entry was 41.3 ± 12.0 years and 51.8% were women. A total of 38% had had relapse activity during the 12 months before starting on ocrelizumab, with a mean relapse rate of 1.3 ± 0.6 during that period. 75% were free from clinical relapses and 91% were free from gadolinium-enhancing lesions in the relapsing-remitting course. Ocrelizumab discontinuation during the first 12 months was observed in three patients (3.7%). The mean persistence observed during the first-year follow-up was 338 ± 24 days. Conclusions: Our study is in line with previous randomized clinical trials and recent real-world studies describing patient profiles, effectiveness and persistence regarding ocrelizumab treatment in multiple sclerosis patients in Latin America.

RESUMEN Introducción: A pesar de la abundante información sobre ocrelizumab proveniente de los ensayos clínicos de fase III, todavía se tiene poca evidencia sobre la efectividad y el perfil de pacientes provenientes de la vida real. Objetivo: Evaluar el perfil clínico y demográfico, la efectividad y la persistencia al tratamiento en pacientes que usaron el ocrelizumab para el tratamiento de esclerosis múltiple (EM) en Latinoamérica. Métodos: Estudio retrospectivo multicéntrico en Argentina, Chile y México. Se analizaron los datos de los pacientes que recibieron ocrelizumab. Se describieron las variables demográficas y clínicas, así como los resultados de efectividad que incluyeron la proporción de pacientes libres de recaídas clínicas, libres de progresión de la discapacidad, libres de nuevas lesiones en la secuencia T2 o T1 con gadolinio durante el seguimiento. Resultados: Se incluyeron 81 pacientes. El fenotipo más frecuente fue EM remitente recurrente (EMRR) en el 64,2% de los pacientes. La edad media fue de 41.3±12 años, y el 51,8% eran mujeres. Un total de 38% tuvo recaídas durante los 12 meses previos al inicio de ocrelizumab, con una tasa anualizada de recaídas media de 1.3±0.6 durante ese período. En el seguimiento a 12 meses, el 75% estuvo libre de recaídas clínicas y el 91%, libre de nuevas lesiones en RM. Tres pacientes interrumpieron el tratamiento durante el seguimiento (3,7%). La persistencia al tratamiento observada durante el primer año de seguimiento fue de 338±24 días. Conclusión: Nuestro estudio está en línea con los datos provenientes de ensayos clínicos aleatorizados previos y estudios recientes del mundo real que describen la efectividad de los perfiles de pacientes y la persistencia al tratamiento con ocrelizumab en pacientes con EM en Latinoamérica.

Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists.

Introduction: According to previous studies, therapeutic inertia (TI) may affect 7 out of 10 physicians who care for MS patients, particularly in countries where clinical guidelines are not widely used. Limited information is available on the prevalence of TI and its associated factors across Canada. Objectives: (i) To evaluate factors associated with TI amongst neurologists caring for MS patients across Canada; (ii) to compare the prevalence of TI observed in Canadian neurologists to the prevalence of TI observed in Argentinean, Chilean, and Spanish neurologists (historical controls from prior studies). Design: One hundred and eight neurologists with expertise in MS were invited to participate in an online study in Canada. Participants answered questions regarding their clinical practice, risk preferences, management of 10 simulated case-scenarios. The design of that study was similar to that of the prior studies completed in Argentina and Chile (n = 115). TI was defined as lack of treatment initiation or escalation when there was clear evidence of clinical and radiological disease activity (8 case-scenarios, 440 individual responses). A TI score was created & defined as the number of case-scenarios that fit the TI criteria over the total number of presented cases (score range from 0 to 8), with a higher score corresponding to a higher TI. TI scores observed in the Canadian study were compared with those observed in Argentina and Chile, as both studies followed the same design, case-scenarios and methodologies. Predictors of TI included demographic data, MS specialist vs. general neurologist, practice setting, years of practice, volume of MS patients and risk preferences. Results: Fifty-five Canadian neurologists completed the study (completion rate: 50.9%). The mean age (±SD) was 38.3 (±15) years; 47.3% of the participants were female and 56.4% self-identified as MS specialists. Overall, 54 of 440 (12.3%) individual responses were classified as TI. 60% of participants displayed TI in at least one case-scenario. The mean TI score across Canada [0.98 (SD = 1.15)] was significantly lower than the TI score observed in the Argentinean-Chilean [1.82 (SD = 1.47); p < 0.001] study. The multivariable analysis revealed that older age (p = 0.018), years of experience (p = 0.04) and willingness to risk further disease progression by avoiding treatment initiation or treatment change (p = 0.043) were independent predictors of TI. Conclusions: TI in Canada was observed in 6 out of 10 neurologists, affecting on average 1 in 8 therapeutic decisions in MS care. TI in Canada is significantly lower than in the other studied countries. Factors associated with TI include older age, lower years of experience, and willingness to risk disease progression by avoiding treatment initiation or treatment change. Differences in clinical practice patterns and adherence/access to accepted MS guidelines may explain how TI in Canada differs significantly from TI in Argentina-Chile.

Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America.

Despite the availability of a large amount of information regarding the management and care of relapsing remitting multiple sclerosis (RRMS) patients, there is scant information about recommendations on how to care for primary progressive MS (PPMS) patients. The objective of this study was to review how PPMS patients should be assessed and cared for in Latin America (LATAM). METHODS: A panel of neurology experts from LATAM dedicated to the diagnosis and care of MS patients gathered virtually during 2017 and 2018 to carry out a consensus recommendation on the diagnosis and treatment of PPMS patients in LATAM. To achieve consensus, the methodology of "formal consensus-RAND/UCLA method" was used. RESULTS: Recommendations focused on disease management, and specific and symptomatic disease treatment were determined. The main consensus was that the 2017 McDonald criteria should be used for diagnosis but that the exclusion of regional diseases is strongly recommended; that specific considerations should be taken regarding immunotherapy treatments used in MS due to the scarce evidence available; and that a general approach that considers symptomatic treatment and rehabilitation should be performed in affected patients to improve their status. CONCLUSIONS: The recommendations of these consensus guidelines attempt to optimize the health care and management of PPMS patients in LATAM.

NeuroSPECT de la penumbra isquémica en infarto cerebral agudo y pronóstico de recuperabilidad / NeuroSPECT of the ischemic penumbra in acute brain infarct and viability prognosis

El infarto cerebral agudo representa una emergencia clínica, potencialmente reversible si se trata con trombolisis durante las primeras 3 a 6 horas de evolución. La reversibilidad del cuadro clínico es función, entre otros factores, del grado de profundidad de la hipoperfusión en la región cerebral comprometida. Otros factores que inciden en la reversibilidad del cuadro clínico es el tiempo transcurrido desde el inicio de la sintomatología antes del tratamiento y la recanalización del vaso obstruido. Presentamos dos casos de infarto cerebral embólicos que fueron estudiados con SPECT Cerebral y tratados con trombolisis cerebral durante las primeras 3 horas de evolución. El primer caso se trataba de una cardioembolía en “T” con oclusión de la carótida interna distal y de las arterias cerebral anterior y media proximales izquierdas y el segundo caso es de una cardioembolía con oclusión de la arteria cerebral media derecha desde su origen. La evolución de ambos casos fue diametralmente diferente y analizamos en este trabajo los resultados de la cuantificación de la hipoperfusión en la zona infartada con objeto de definir factores pronósticos de estos pacientes y la indicación de trombolisis arterial.

Tc99m-HMPAO Neuro--SPECT assessment of ischemic penumbra in acute brain infarct: control of intra-arterial thrombolysis treatment

El infarto cerebral agudo representa una emergencia clínica, potencialmente reversible si se trata con trombolisis durante las primeras 3 a 6 horas de evolución. La trombolisis tiene muchas ventajas para el paciente, pero también representa algunos riesgos como el desarrollo de una hemorragia intracerebral. Como consecuencia de un intenso trabajo de investigación contamos hoy dia con importantes avances en diferentes técnicas de neuro-imágenes para evaluar la isquemia cerebral potencialmente reversible, incluyendo la resonancia magnética (RM) con difusión-perfusión, la tomografía computada (CT) con perfusión y estudios neurofuncionales como el PET y el SPECT cerebral. Este trabajo comunica los resultados en la evaluación pre y post tratamiento endovascular en una serie de pacientes que presentaron isquemia cerebral aguda y luego fueron tratados con trombolisis intra-arterial cerebral. MÉTODO: 16 pacientes fueron tratados de forma aguda por un infarto cerebral agudo siguiendo el siguiente protocolo: 1) Admisión y evaluación completa neurológica. 2) TAC cerebral para descartar presencia de hemorragia cerebral o de un infarto cerebral establecido. 3) Inyección endovenosa de 1100MBq Tc99mm HMPAO (Ceretecmr) 4) Angiografía cerebral convencional y trombolisis intra-arterial cerebral con tPA y posible angioplastía y colocación de stent. 5) Adquisición de imágenes de NeuroSPECT para evaluar penumbra isquémica (resultados pre-terapia) 6) 14 de 16 pacientes recibieron NeuroSPECT de control a las 24 horas (resultados post-terapia). La adquisición de imágenes de NeuroSPECT fue inmediatamente después de la trombolisis utilizando una cámara de doble cabezal, Siemens ECAM, SHR colimador utilizando protocolo habitual. Las imágenes fueron procesadas utilizando un software Neurogam de Segami Corp. previamente reportado en Alasbimn Journal 2(7):Abril 2000. http://www.alasbimnjournal.cl El análisis estadístico consistió en 1) normalización del volumen cerebral de acuerdo al mapa.

[Disulfiram neuropathy. Report of 3 cases]. / Neuropatía por disulfiram. Comunicación de tres casos clínicos.

Disulfiram is widely used for aversive treatment of alcoholism. Although it is well tolerated in most patients, one in 15,000 patients will develop peripheral neuropathy every year, which is frequently misdiagnosed as alcoholic neuropathy. Disulfiram neuropathy can be mild or severe, depending on diverse factors such as time of exposure and the dosage. Most patients will present with a motor-sensory neuropathy of the lower limbs, which tends to improve as disulfiram administration ceases, however some cases may remain with permanent sequelae. We report the clinical, laboratory and electrophysiological features of three patients who developed disulfiram neuropathy during treatment of alcoholism. Recovery was incomplete at 8 weeks after treatment cessation in all of them. No other findings justified the clinical features described in these patients. Considering the incidence of alcoholism and the wide use of disulfiram treatment in Chile, we suggest that disulfiram neuropathy is being underdiagnosed. We also stress the fact that disulfiram neuropathy could be avoided by using lower doses.

Neuropatías autoinmunes: parte I: neuropatías y anticuerpos antineuronales / Autoimmune neurophaties: part I: neuropathy and antineural antibodies

Se trata de la primera parte de 2 artículos tendientes a aclarar el valor de exámenes serológicos en el diagnóstico de las neuropatías autoinmunes. Específicamente de los anticuerpos antineurales y de las gamapatías monoclonales. En esta primera revisión se presentan las posibilidades y limitaciones de los anticuerpos antineurales en manejo clínico de estas neuropatías. En primer lugar se describen las características generales de los distintos tipos de anticuerpos. Los síndromes polineuropáticos han sido divididos en motores, sensitivos, sensitivo/motores y Guillain-Barré, discutiéndose para cada caso la utilidad diagnóstica de los distintos anticuerpos antineurales